NCT03100864View on ClinicalTrials.gov

This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

August 5, 2019

Study Completion Date

October 24, 2019

Conditions
Colitis, Ulcerative
Interventions
DRUG

Spesolimab

12 weeks treatment

Trial Locations (4)

3000

UZ Leuven, Leuven

22559

Asklepios Kliniken Westklinikum Hamburg, Hamburg

24105

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel

CB2 0QQ

Addenbrooke's Hospital, Cambridge

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY